Synthetic Glycan-Conjugate Platforms for Mimicking Viral Glycan Shields and Eliciting Broad-Spectrum Immune Responses
Scientists created virus-like particles densely coated with synthetic oligomannose sugars to mimic viral glycan shields, enabling strong immune recognition and neutralization of viruses like SARS-CoV-2, offering a promising approach for broad-spectrum antiviral vaccines.
Background
The development of broad-spectrum vaccines and antiviral therapies is crucial for combating rapidly evolving viral pathogens, such as coronaviruses. Many viruses employ a dense ‘glycan shield’ on their surface proteins, which helps them evade immune detection. However, these shields also contain conserved carbohydrate structures, particularly oligomannoses, that are vital for viral function and represent vulnerable targets. There is a pressing need to identify and effectively present these conserved glycan epitopes to the immune system to elicit potent, protective antibody responses capable of neutralizing diverse viral strains.
A significant challenge in utilizing these glycan targets lies in their inherent fragility; high-mannose glycans are susceptible to enzymatic degradation by host α-mannosidases, leading to in vivo instability. This instability can compromise their integrity and immunogenicity, making it difficult to generate a sustained and robust immune response. Furthermore, some existing synthetic approaches for presenting glycan epitopes may not adequately mimic the high-density, ordered arrangement found on viral surfaces, potentially leading to suboptimal antibody production or the generation of antibodies that target less relevant glycan substructures rather than the desired virus-neutralizing epitopes.
Technology
This technology involves synthetic high-density oligomannose-conjugates, primarily utilizing bacteriophage Qβ virus-like particles (VLPs) as scaffolds. These constructs are engineered by chemically attaching high-mannose N-glycans, such as Man9GlcNAc2, to azide-modified Qβ VLPs using copper(I)-catalyzed azide-alkyne cycloaddition. This process enables the display of approximately 450 oligomannose glycans per Qβ particle in a dense and ordered configuration, effectively mimicking the glycan shield found on viruses like SARS-CoV-2. These synthetic structures recreate GNA+ virus-neutralizing glyco-epitopes, showing strong reactivity with the mannose-specific lectin GNA and eliciting specific IgG antibodies from convalescent sera.
The distinctiveness of this approach lies in the use of Qβ VLPs, which provide a superior scaffold for presenting these glyco-epitopes compared to soluble protein carriers. Their multivalent and rigid architecture allows for an exceptionally dense and ordered display of oligomannoses, closely mimicking the presentation on actual viral surfaces. This precise arrangement is crucial for eliciting a targeted immune response, as demonstrated by the specific IgG antibodies that recognize the oligomannose moieties rather than common glycan core structures. This offers a promising strategy for developing broad-spectrum vaccine candidates by targeting conserved glycan shields across diverse viruses.
Benefits
- Mimics virus glycan shields by densely displaying oligomannose glycans on Qβ virus-like particles (VLPs)
- Effectively recreates broad-spectrum virus-neutralizing glyco-epitopes recognized by mannose-specific lectins and antibodies
- Induces strong, specific IgG antibody responses targeting conserved oligomannose epitopes found on SARS-CoV-2 and other coronaviruses
- Qβ VLP platform provides superior multivalent and ordered glycan presentation compared to traditional protein carriers
- Potential to serve as a vaccine candidate eliciting broad-spectrum neutralizing antibodies against glycan-shielded viruses
- Enables detailed glyco-epitope mapping and immunological profiling using carbohydrate microarrays
- Facilitates synthetic and scalable production of defined glycan conjugates with controlled density and structure
Applications
- Broad-spectrum antiviral vaccine development
- Virus-neutralizing antibody screening
- Glyco-epitope mapping diagnostics
- Antiviral lectin therapeutic research
Additional info
These synthetic high-density oligomannose-conjugates utilize Qβ virus-like particles as scaffolds. High-mannose N-glycans, functionalized with alkynes, are covalently attached to azide-modified Qβ VLPs via copper(I)-catalyzed azide-alkyne cycloaddition. This process densely displays ~450 oligomannose glycans, mimicking viral glycan shields and recreating GNA+ virus-neutralizing glyco-epitopes. They elicit specific IgG antibodies, despite in vivo instability from α-mannosidase susceptibility.